Wound Management Technologies, Inc. Retains KCSA Strategic Communications as U.S. Investor Relations Counsel


Follow this company

Companies Mentioned

OTC:BB:WNDM
07/31/2014 [ACCESSWIRE]

Addison, TEXAS / ACCESSWIRE / July 31, 2014 / Wound Management Technologies, Inc. (OTC BB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA- approved collagen product, CellerateRX(R), today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's investor relations program.

KCSA intends to deploy a comprehensive investor relations communication campaign designed to increase awareness of Wound Management Technologies among the U.S. investment community.  Since KCSA’s inception over forty years ago, the firm has developed a strong reputation for its work representing public companies.  Todd Fromer, Managing Partner of KCSA, will lead the KCSA team and provide strategic counsel on financial communication matters.

"We are excited to begin working with KCSA in order to generate greater investor awareness for Wound Management Technologies and the progress we have made over the last year in turning the Company around," said Robert Lutz, Jr., Wound Management’s Chairman and Chief Executive Officer.  "Our CellerateRX(R) product will be transformational in how physicians treat wounds across the healthcare system.  With KCSA’s proactive approach to our communications program, we will highlight the growth potential for our business to shareholders and the inherent value of our product pipeline as we further penetrate the wound care and surgical market."

Mr. Fromer stated, "With an experienced management team led by Robert Lutz, Jr., Wound Management Technologies is an exciting growth story that investors should become familiar with as they execute their strategy. We believe KCSA can play an important role in generating greater investor awareness as the Company’s primary product, CellerateRX(R), increases sales and expand its product offerings."  

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market.  Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX(R), which is FDA-approved and reimbursable under Medicare Part B.  Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development.  For more information visit www.wmgtech.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and marketing with expertise in financial and professional services, technology, healthcare, media, energy and public services companies. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

Information about Forward-Looking Statements
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

KCSA Strategic Communications
Todd Fromer / Garth Russell
+ 212-682-6300
Tfromer@kcsa.com / Grussell@kcsa.com

SOURCE: Wound Management Technologies, Inc.

COMMENTS

Leave a comment...
 * 

Your Name
 *